Adrian Rawcliffe: Okay. So why don’t I take a stab at what I’m most excited about from a tech platform perspective. Garry, I think you could do the same. And I’m actually going to focus on — I’m going to focus on 3 things that I think are really, really interesting from this — from a technical perspective. I’m going to go with the first. First is the combination of the fundamental platforms is actually really interesting. We will then have access to the entire target universe. And I will point out that TCR2 are, I believe, the only company who have a robust efficacy signal with a mesothelin-targeting — targeted cell therapy. And I think that is indicative of the potential of the TRuC platform for cell surface antigens. And between the two of us, we then cover the entire target universe, point one.
Secondly, I think the combination of the next-generation approaches has a lot of leverage associated with it. I’m particularly interested personally, given the clinic — in clinical development in the PD-1 CD28 switch that operates differently to most — our existing next-generation approaches. And I think that would be really interesting to see the applicability of this. And then, lastly, I think the opportunity to – and this is obviously over the longer term to take the border pipeline and put it onto am Adaptimmune allogeneic platform as that matures, I think, is also a really key long-term benefit of this combination. Garry?
Garry Menzel: So Asthika, since Ad has basically managed to grab all of the innovations and tell you about them, I’m going to…
Adrian Rawcliffe: Still got membrane balance, obviously, Garry.
Garry Menzel: That is very true. I guess I could throw that in there. But I’ll tell you what, I’m in some respects most excited about it perhaps a softer issue. That’s a really important one that almost gets to your first comment about is this the beginning of consolidation within the cell therapy space on the solid tumor side. And that is that what I’ve observed is the leadership teams on the scientific side in these conversations have been excited about each of its technologies and begun riffing over what they might do together in the future, new ideas that will emerge from the combination of the company — the two companies into one combined entity. I really do feel that there’s going to be a lot of innovation that comes out of that. And this is a space where we do need continued innovation. So beyond the items that were mentioned by Ad, which I fully endorse, I’m really excited about what the teams will create together going forward.
Adrian Rawcliffe: And then your next question was on sort of manufacturing capability and manufacturing capacity and things like that and access to that for the — and I think there’s an interesting balance that we’ll need to play out over time. So one of the things that I am really excited about is both of our companies are very pragmatic when it comes to developing cell therapies. I think developing cell therapies teaches you humility and it teaches you pragmatism. And so we are going to need to make pragmatic choices about the development of these on the basis of the existing platforms that we’ve got. And largely, TCR2 is on a Miltenyi Prodigy platform. And largely, we are on other platforms that we’ve developed internally, 2 different ones for afami-cel and CD8.
Having said that, over time, there is obviously the opportunity to either bring the Miltenyi Prodigy platform into our capacity, our capabilities and/or as the pipelines evolve, move to common manufacturing processes over time. And so that’s an obvious synergy. And I just want to point out something that’s really interesting about these companies. As you put the two – as you think about putting the two together, I would encourage you to think about the fit of these companies because we are both solid tumor, both engineered TCR-cell therapies. We both use a number of the same platforms and approaches. And just pick one, the lentiviral vector transduction to insert the genetic material into the cell. We’re both on common platforms. We have for some of this.
